AbbVie
The latest news about AbbVie: headlines, AI summaries and the full story from every source.
- AbbVie's Rinvoq Shows Continued Repigmentation in Patients with Non-Segmental Vitiligo Through Week 76
- AbbVie's Migraine Drug Qulipta Achieves Key Clinical Milestone
- AbbVie Reports Strong Phase 3 Results for Myeloma Treatment Etentamig
- Billionaire Israel 'Izzy' Englander Increases Stake in AbbVie and Invests in SpaceX
- AbbVie Outlines Growth in SKYRIZI, RINVOQ and Pipeline Advances at Wells Fargo Conference
- Ken Griffin Increases Stake in AbbVie and Abbott Laboratories
- AbbVie's Stock Continues Decline for Seventh Consecutive Session
- Skyrizi Growth Deceleration Could Test AbbVie Stock
- AbbVie Inc. (ABBV) Announces New Data on Venetoclax-Based Combination Therapy
- Johnson & Johnson Launches New Plaque Psoriasis Treatment Competing with AbbVie’s Skyrizi
- Johnson & Johnson Launches New Plaque Psoriasis Treatment to Challenge AbbVie’s Skyrizi
- Johnson & Johnson vs AbbVie: Divergent Growth Strategies in Q1 2026 Earnings
- A Small Biotech Shows Competitive Potential Against AbbVie's Key Drug
- AbbVie's Q1 Revenue Surpasses Expectations with Strong Performance in Immunology
- AbbVie Reports Strong First-Quarter Results with Revenue Growth and Outperforming Immunology Drugs
- AbbVie Submits FDA Application for Subcutaneous Version of Skyrizi
- AbbVie Receives FDA CRL for Wrinkle Drug Due to Manufacturing Concerns